Outcomes of an Intravenous to Subcutaneous Infliximab ( <scp>CT</scp> ‐ <scp>P13</scp> ) Strategy in Takayasu Arteritis: A Proof‐of‐Concept Prospective Study
IV-IFX to SC-IFX switching was feasible and well tolerated and generally maintained remission over 12 months in most patients with TA, with stable metabolic imaging and no increase in damage accrual. These findings support SC-IFX as a practical maintenance strategy, warranting confirmation in larger multicenter cohorts.
Authors
- Roberto Padoan (ORCID: https://orcid.org/0000-0002-2356-375X)
- Luca Iorio (ORCID: https://orcid.org/0009-0000-2388-7001)
- F. Davanzo (ORCID: https://orcid.org/0009-0004-9429-419X)
- M. Codirenzi
- Eleonora Fiorin
- R. Prevedello
- Andrea Doria
Institutions
- University of Padua (IT)
Publication Details
- Journal
- ACR Open Rheumatology
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1002/acr2.70158
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00